Jazz Pharmaceuticals plc Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Jazz Pharmaceuticals plc stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $10.90M.
- Jazz Pharmaceuticals plc stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $32.90M, a 186.09% increase year-over-year.
- Jazz Pharmaceuticals plc stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $733.00K, a 4211.76% increase year-over-year.
- Jazz Pharmaceuticals plc stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Jazz Pharmaceuticals plc stock issued during period, value, stock options exercised for fiscal 2025 was $88.47M, a 5330.94% increase from fiscal 2024.
- Jazz Pharmaceuticals plc stock issued during period, value, stock options exercised for fiscal 2024 was $1.63M, a 94.60% decline from fiscal 2023.
- Jazz Pharmaceuticals plc stock issued during period, value, stock options exercised for fiscal 2023 was $30.19M, a 63.58% decline from fiscal 2022.
- Jazz Pharmaceuticals plc stock issued during period, value, stock options exercised for fiscal 2022 was $82.90M, a 30.37% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $10.90M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $32.90M 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $88.47M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $733.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-11-05 | |
| 2025-03-31 | $11.50M 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $1.63M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $17.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $54.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $494.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $30.19M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $5.51M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $2.00M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $21.23M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $82.90M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $21.26M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $16.64M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $21.73M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $119.06M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $14.82M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $43.60M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $50.41M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $86.98M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $10.09M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $4.44M 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $13.26M 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $46.48M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $9.97M 10-Q · filed 2020-11-02 | |
| 2019-06-30 | $7.03M 10-Q · filed 2020-11-02 | |
| 2019-03-31 | $3.06M 10-Q · filed 2020-11-02 | |
| 2018-12-31 | $82.92M 10-K · filed 2021-02-23 | |
| 2018-09-30 | $17.00M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $51.02M 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $10.59M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $22.68M 10-K · filed 2020-02-25 | |
| 2016-12-31 | $16.88M 10-K · filed 2019-02-26 | |
| 2015-12-31 | $32.98M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $43.04M 10-K · filed 2017-02-28 | |
| 2013-12-31 | $20.89M 10-K · filed 2016-02-23 | |
| 2012-12-31 | $14.21M 10-K · filed 2015-02-24 | |
| 2011-12-31 | $12.21M 10-K · filed 2014-02-25 | |
| 2010-12-31 | $3.68M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |